<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5950">
  <stage>Registered</stage>
  <submitdate>13/06/2016</submitdate>
  <approvaldate>13/06/2016</approvaldate>
  <nctid>NCT02823145</nctid>
  <trial_identification>
    <studytitle>An Open-Label Extension Trial to Assess the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride HCl) Oral Solution in Children and Young Adults With Dravet Syndrome</studytitle>
    <scientifictitle>An Open-Label Extension Trial to Assess the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride HCl) Oral Solution as an Adjunctive Therapy in Children and Young Adults With Dravet Syndrome</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>ZX008-1503</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Dravet Syndrome</healthcondition>
    <conditioncode>
      <conditioncode1>Other</conditioncode1>
      <conditioncode2>Research that is not of generic health relevance and not applicable to specific health categories listed above</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Epilepsy</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - ZX008 (Fenfluramine Hydrochloride)

Experimental: ZX008 - ZX008 is supplied as an oral solution in a concentration of 2.5 mg/mL. Subjects will be titrated to an effective dose beginning with 0.2 mg/kg/day (maximum: 30 mg/day).


Treatment: drugs: ZX008 (Fenfluramine Hydrochloride)


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Long-term safety and tolerability as measured by treatment emergent adverse events, including clinical labs, vital signs, and examination findings. - Sensitivity of the key efficacy analysis will be assessed for changes in dose or type of concomitant AED medications</outcome>
      <timepoint>Pre-baseline Up to 54 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of subjects who achieve reduction from baseline in convulsive seizure frequency</outcome>
      <timepoint>Baseline up to 54 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The longest interval between convulsive seizures will be calculated for each subject over the entire open-label treatment period.</outcome>
      <timepoint>Up to 54 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Key 

          -  Male or non-pregnant, non-lactating female, age 2 to 18 years, inclusive as of the day
             of the core study Screening Visit.

          -  Satisfactory completion of the core study in the opinion of the investigator and the
             sponsor.

          -  A documented medical history to support a clinical diagnosis of Dravet syndrome, where
             convulsive seizures are not completely controlled by current antiepileptic drugs.

          -  Parent/caregiver is willing and able to be compliant with diary completion, visit
             schedule and study drug accountability.

          -  Subject's parent/caregiver has been compliant with diary completion during the core
             study, in the opinion of the investigator (eg, at least 90% compliant).

        Key</inclusivecriteria>
    <inclusiveminage>2</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>18</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Current or past history of cardiovascular or cerebrovascular disease, myocardial
             infarction or stroke.

          -  Current cardiac valvulopathy or pulmonary hypertension that the investigator, parent,
             IPCAB, IDSMC, or sponsor deems clinically significant and warrants discontinuation of
             study medication.

          -  Current or past history of glaucoma.

          -  Moderate or severe hepatic impairment.

          -  Receiving concomitant therapy with: centrally-acting anorectic agents;
             monoamineoxidase inhibitors; any centrally-acting compound with clinically appreciable
             amount of serotonin agonist or antagonist properties, including serotonin reuptake
             inhibition; atomoxetine, or other centrally-acting noradrenergic agonist;
             cyproheptadine, and/or cytochrome P450 (CYP) 2D6/3A4/2B6 inhibitors/substrates.

          -  Currently taking carbamazepine, oxcarbamazepine, eslicarbazepine, phenobarbital, or
             phenytoin, or has taken any of these within the past 30 days, as maintenance therapy.

          -  Currently receiving or has received stiripentol in the past 21 days prior to Visit 1.

          -  Unwilling to refrain from large or daily servings of grapefruits and/or Seville
             oranges, and their juices beginning with the Visit 1 and throughout the study.

          -  A clinically significant condition, or has had clinically relevant symptoms or a
             clinically significant illness at Visit 1, other than epilepsy, that would negatively
             impact study participation, collection of study data, or pose a risk to the subject.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/06/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>210</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/12/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Melbourne Brain Centre Austin Hospital - Melbourne</hospital>
    <hospital>Princes Margaret Hospital - Perth</hospital>
    <hospital>Children's Health Queensland Hospital and Health Service at Lady Cilento Children's Hospital - South Brisbane</hospital>
    <hospital>The Children's Hospital Westmead Dept. of Neurology and Neurosurgery - Westmead</hospital>
    <postcode> - Melbourne</postcode>
    <postcode> - Perth</postcode>
    <postcode> - South Brisbane</postcode>
    <postcode> - Westmead</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Antwerp</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Dianalund</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bielefeld</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Freiburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Jena</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Radeberg (Sachsen)</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>TÃ¼bingen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Vogtareuth</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Genova</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Mantova</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milano</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Verona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Pamplona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Gothenburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Birmingham</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Glasgow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Liverpool</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Sheffield</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is an international, multicenter, open-label, long-term safety study of ZX008 in
      pediatric and young adult subjects with Dravet syndrome who have successfully completed 14
      weeks of treatment in the core study (ZX008-1501 and ZX008-1502).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02823145</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>